Brigham and Women's Hospital

This year’s American Society of Hematology (ASH) meeting delivered positive Phase II results for a new daily oral therapy and promising interim Phase I/II data for a one-time base editing treatment fo

Amgen, Inc. chief technology officer David Reese, who recently handed over his prior title of EVP of research and development to Jay Bradner, explained in an interview with Scrip during this month’

Amgen, Inc. has doubled the leadership of its research and development efforts, announcing on 14 December that it recruited former Novartis Institutes for BioMedical Research Inc. (NIBR) president

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daewoong, HanAll Co-Invest In Vinc